Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
Ron DePinho, Professor at Department of Cancer Biology, Harry Graves Burkhart III Distinguished University Chair Cancer Biology at MD Anderson Cancer Center, shared a post on LinkedIn:
“Disappointing for this program, but definitely not a repudiation of inflammation as a cardiovascular target.
The key question will be whether the trial tested the right inflammatory biology, in the right patients, at the right stage of disease.
Cardiovascular inflammation is not a single pathway or biomarker; it is a dynamic network shaped by residual lipid risk, obesity and metabolic dysfunction, clonal hematopoiesis, immune aging, and tissue injury.
The field should learn as much from a negative trial as from a positive one.
We need better mechanistic patient stratification, pharmacodynamic biomarkers that demonstrate pathway engagement in the relevant tissue, and combination strategies matched to the biology of residual risk.
The inflammatory hypothesis remains compelling in my view… it is likely that its clinical translation clearly requires greater precision.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment
-
Oct 19, 2026, 16:04Hussnain Javaid: New EHA Guidelines for HbSC Disease Management
-
Oct 19, 2026, 15:50Deep Madkaiker: A New Academic Opportunity in Transfusion Medicine at ACTREC
-
Oct 19, 2026, 15:19Why Hematologists Should Care About Diminished Ovarian Reserve in SCD – ASH Education
-
Oct 19, 2026, 14:16Hyperfibrinolysis as an Underrecognized Cause of Bleeding
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026